Competitor Analysis: TNF Antibodies 2015– Biosimilars and Biosuperiors of Humira, Remicade and Enbrel
Competitor Analysis: TNF Antibodies 2015– Biosimilars and Biosuperiors of Humira, Remicade and Enbrel
The present Competitive Intelligence report about TNF Antibodies 2015– Biosimilars and Biosuperiors of Humira, Remicade and Enbrel provides a competitor evaluation in the field of recombinant antibodies targeting tumor necrosis factor (TNF) alpha or its receptor used to treat various inflammatory and autoimmune diseases as of March 2015. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The five branded anti-TNF antibodies Humira, Remicade, Enbrel, Simponi and Cimzia together achieved global sales of US$ 34. 4 bln (+12. 9%) in the year 2014. While the first biosimilars of Humira, Remicade and Enbrel are already marketed in less regulated countries such as India and China, it is only in February of 2015 that a biosimilar TNF antibody has been launched in the European Union. The Marketing Authorization Applications of further two biosimilar TNF antibodies have been just been submitted to the European Medicines Agency and the clinical pipeline of is rather full.
The report includes a compilation of currently active R&D projects of TNF targeting antibodies for treatment of inflammatory and autoimmune diseases. In addition, the report lists company-specific R&D pipelines of TNF antibodies. Competitor projects are listed in a tabular format providing information on:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
The present Competitive Intelligence report about TNF Antibodies 2015– Biosimilars and Biosuperiors of Humira, Remicade and Enbrel provides a competitor evaluation in the field of recombinant antibodies targeting tumor necrosis factor (TNF) alpha or its receptor used to treat various inflammatory and autoimmune diseases as of March 2015. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The five branded anti-TNF antibodies Humira, Remicade, Enbrel, Simponi and Cimzia together achieved global sales of US$ 34. 4 bln (+12. 9%) in the year 2014. While the first biosimilars of Humira, Remicade and Enbrel are already marketed in less regulated countries such as India and China, it is only in February of 2015 that a biosimilar TNF antibody has been launched in the European Union. The Marketing Authorization Applications of further two biosimilar TNF antibodies have been just been submitted to the European Medicines Agency and the clinical pipeline of is rather full.
The report includes a compilation of currently active R&D projects of TNF targeting antibodies for treatment of inflammatory and autoimmune diseases. In addition, the report lists company-specific R&D pipelines of TNF antibodies. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
1. TNF Antibodies 2015 – Biosimilars and Biosuperiors of Humira, Remicade and Enbrel
Tab. 1: Approved and marketed indications of anti-TNF antibodies in regulated markets
Tab. 2: Additional indications of branded anti-TNF antibodies under development
Tab. 3: 2014 Sales of anti-TNF Antibodies
Marketed TNF Antibodies
Humira Sales & Pipeline
Remicade Sales & Pipeline
Enbrel Sales & Pipeline
Simponi Sales & Pipeline
Cimzia Sales & Pipeline
Biosuperior / Biobetter TNF Antibodies
Biosimilar TNF Antibodies
Humira Biosimilar Antibody Pipeline
Remicade Biosimilar Antibody Pipeline
Enbrel Biosimilar Antibody Pipeline
Cimzia Biosimilar Antibody Pipeline
2. Corporate TNF Antibody Biosimilar & Biosuperior Pipelines
Tab. 1: Approved and marketed indications of anti-TNF antibodies in regulated markets
Tab. 2: Additional indications of branded anti-TNF antibodies under development
Tab. 3: 2014 Sales of anti-TNF Antibodies
Marketed TNF Antibodies
Humira Sales & Pipeline
Remicade Sales & Pipeline
Enbrel Sales & Pipeline
Simponi Sales & Pipeline
Cimzia Sales & Pipeline
Biosuperior / Biobetter TNF Antibodies
Biosimilar TNF Antibodies
Humira Biosimilar Antibody Pipeline
Remicade Biosimilar Antibody Pipeline
Enbrel Biosimilar Antibody Pipeline
Cimzia Biosimilar Antibody Pipeline
2. Corporate TNF Antibody Biosimilar & Biosuperior Pipelines
